Synmosa Biopharma : Announcement of the second session of the audit committee and the fourth session of the compensation committee of the Company Term Expiration Matters
Announcement of the second session of the audit
committee and the fourth session of the compensation
committee of the Company Term Expiration Matters
Date of events
2022/05/25
To which item it meets
paragraph 6
Statement
1.Date of occurrence of the change:2022/05/25
2.Name of the functional committees:
Audit Committee and Compensation Committee
3.Name of the previous position holder:
Fan, De-Quan
Liu, Xiang-Lang
Lin, Xiu-Mei
4.Resume of the previous position holder:
Independent Director of the company
Independent Director of the company
Independent Director of the company
5.Name of the new position holder:
Liu, Xiang-Lang
Lin, Xiu-Mei
Wang Chien-Jen
6.Resume of the new position holder:
Independent Director of the company
Independent Director of the company
General manager, Rich Wang Plastic Co., Ltd.
7.Circumstances of change (Please enter "resignation", "dismissal",
"term expired", "death" or "new appointment"):term expired
8.Reason for the change:
Cooperate with the expiry of the term of the director to carry
out comprehensive re-election, and the term of office is the same
as the term of the board of directors
9.Original term (from __________ to __________):
from 2019/05/24~2022/05/23
10.Effective date of the new member:
from 2022/05/25~2025/05/24
11.Any other matters that need to be specified:
The fourth term of compensation and remuneration committee
members will be announced later after the appointment of the
board of directors.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Synmosa Biopharma Corporation published this content on 25 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 May 2022 16:11:30 UTC.
SYNMOSA BIOPHARMA CORPORATION is a Taiwan-based company principally engaged in the manufacture and sales of various kinds of pharmaceuticals and medical equipment. The Company's main products include respiratory drugs, cardiovascular and urinary drugs, gastrointestinal drugs, hormones, anti-tumor drugs, antibiotics and health products. The Company is also involved in the manufacture and sales of various kinds of cosmetics and animal medicines, as well as various kinds of chemical food additives and beverages. The Company distributes its products in domestic market and to overseas markets.
Synmosa Biopharma : Announcement of the second session of the audit committee and the fourth session of the compensation committee of the Company Term Expiration Matters
SYNMOSA BIOPHARMA CORPORATION 
